Drug Price Waterloo: China's New Bidding Process Hits MNCs Hard
Executive Summary
China's new so-called “4+7” drug bidding pilot scheme, already expected to be a killer for some companies, has cut prices by as much as 90%, leaving all but two multinationals to bid successfully and accept the revised levels. The big reductions could also lead to further price erosion for the winning products.
You may also be interested in...
Upjohn/Mylan: Will "Potential Moderate Growth" Lure Investors?
The combined company will have pro forma 2020 revenues of $19bn to $20bn, generate $1bn in synergies by 2023 and be led by Upjohn CEO Michael Goettler. Mylan's longtime CEO Heather Bresch will depart.
GSK Divests China Suzhou Site, Antiviral Rights To Fosun
GSK becomes latest pharma multinational to offload assets in China as competition and pricing pressure continue to mount.
How To Deliver Your China Growth Story: Trends To Watch
Caught between a grueling centralized bidding process and now potentially in trade war crossfire, foreign pharma firms have a lot on their plates in China. To succeed in this highly uncertain environment, observers point to the need to pursue excellence in multiple areas: product launches, medical coverage, the broad market and digital health.